Effects of anti-allergic ophthalmic solutions on chemical mediators in tear fluid and on expression of chemical mediator receptors on conjunctival epithelial cells in patients with allergic conjunctivitis

Effects of anti-allergic ophthalmic solutions on chemical mediators in tear fluid and on expression of chemical mediator receptors on conjunctival epithelial cells in patients with allergic conjunctivitis - Effects of anti-allergic ophthalmic solutions on chemical mediators in tear fluid and on expression of chemical mediator receptors on conjunctival epithelial cells in patients with allergic conjunctivitis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000020490

Enrollment

Registered

2016-01-15

Start date

2016-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergic conjunctivitis

Interventions

Epinastine ophthalmic solution, apply 1 drop a time, 4 times daily, for 12 weeks Olopatadine ophthalmic solution, apply 1 drop a time, 4 times daily, for 12 weeks Artificial tear, apply 2-3 drops a ti

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who has a positive result of type I allergy test by immuno-cap rapid.

Exclusion criteria

Exclusion criteria: 1.Females who are or may be pregnant, or lactating 2.Patients with a history of hypersensitivity to study drug or test material 3.Patient who the investigator considers ineligible for enrolment

Design outcomes

Primary

Measure	Time frame
Expression levels and change in values after 4weeks and 12weeks therapy of chemical mediator receptors on conjunctival epithelial cells	—

Secondary

Measure	Time frame
After 4weeks and 12weeks therapy measured values and change in values of the following Subjective symptom scores Objective finding scores Tear levels of chemical mediators	—

Countries

Japan

Contacts

Public ContactKazuichi Maruyama

Tohoku University Graduate School of Medicine Ophthalmology

maruyama-k@oph.med.tohoku.ac.jp022-717-7000

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026